Population pharmacokinetic analysis from phase i and phase ii studies of the humanized monovalent antibody, onartuzumab (metmab), in patients with advanced solid tumors

Journal of Clinical Pharmacology

Volumn 53, Issue 11, 2013, Pages 1103-1111

  Xin, Yan ^a   Jin, Denise ^a   Eppler, Stephen ^a   Damico Beyer, Lisa A ^a   Joshi, Amita ^a   Davis, John D ^a   Kaur, Surinder ^a   Nijem, Ihsan ^a   Bothos, John ^a   Peterson, Amy ^b   Patel, Premal ^a   Bai, Shuang ^a  

^a GENENTECH INC   (United States)

^b Medivation Inc   (United States)

Author keywords

Erlotinib; MET; Monovalent antibody; Onartuzumab; Pharmacokinetics

Indexed keywords

BEVACIZUMAB; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FC RECEPTOR; ONARTUZUMAB; SCATTER FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; COMPARTMENT MODEL; CREATININE CLEARANCE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TARGETING; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR;

ERLOTINIB; MET; MONOVALENT ANTIBODY; ONARTUZUMAB; PHARMACOKINETICS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES;

EID: 84884566610     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.148     Document Type: Review

References (31)

1. Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007;67:2081-2088.
2. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of cMet and its therapeutic inhibition with SU11274 and small interfering RNA in nonsmall cell lung cancer. Cancer Res. 2005;65:1479-1488.
3. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 2005;7: 436-451.
4. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4: 915-925.
5. Merchant M, Zhang YW, Su Y, et al. Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for cMet inhibitors in combination with EGFR inhibitors. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research April 12-16, 2008, San Diego, CA, USA, Abstract 1336.
6. Chen P, Wang L, Liu B, Zhang HZ, Liu HC, Zou Z. EGFRtargeted therapies combined with chemotherapy for treating advanced nonsmall cell lung cancer: A metaanalysis. Eur J Clin Pharmacol. 2011;67:235-243.
7. Gao H, Ding X, Wei D, et al. Efficacy of erlotinib in patients with advanced nonsmall cell lung cancer: A pooled analysis of randomized trials. Anticancer Drugs. 2011;22:842-852.
8. von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3 05 phase III study in HER2positive breast cancer. Eur J Cancer. 2011;47:2273-2281.
9. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104:20932-20937.
10. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of nonsmall cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res. 2010;70:1625-1634.
11. Pacchiana G, Chiriaco C, Stella MC, et al. Monovalency unleashes the full therapeutic potential of the DN30 antiMet antibody. J Biol Chem. 2010;285:36149-36157.
12. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. 1998;111(Pt 2):237-247.
13. Ridgway JB, Presta LG, Carter P. 'Knobsintoholes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9:617-621.
14. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84: 548-558.
15. Salgia R, Patel P, Bothos J, et al. Phase I doseescalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. submitted to Clinical Cancer Research.
16. Spigel D, Ervin T, Ramlau R, et al. Randomized phase II trial of onartuzumab (MetMAb) in combination with erlotinib in patients with advanced nonsmallcell lung cancer. J Clin Oncol. 2013 (in press).
17. Zhao M, He P, Rudek MA, Hidalgo M, Baker SD. Specific method for determination of OSI774 and its metabolite OSI420 in human plasma by using liquid chromatographytandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2003;793:413-420.
18. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: Problems and solutions. AAPS J. 2009;11:558-569.
19. Ma P, Yang BB, Wang YM, et al. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol. 2009;49:1142-1156.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
21. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol. 2011;29(15 Suppl):Abstract 7505.
22. Lu JF, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with nonsmall cell lung cancer. Clin Pharmacol Ther. 2006;80:136-145.
23. Bai S, Xin Y, Jin D, et al. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody MetMAb in patients with advanced solid tumors. J Clin Oncol. 2011;29(15 Suppl):Abstract 2571.
24. Bender B, Xiang H, Reyes A. Translational pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of MetMAb. Eur J Cancer Suppl. 2008;6:Abstract 540.
25. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633-659.
26. Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ. Pharmacokineticpharmacodynamicefficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res. 2005;22: 1088-1100.
27. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62:779-786.
28. Bai S, Jorga K, Xin Y, et al.A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet. 2012;51:119-135.
29. Xin Y, Bai S, DamicoBeyer LA, et al. Antineuropilin1 (MNRP1685A): Unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharm Res. 2012;29: 2512-2521.
30. Donato MT, GomezLechon MJ, Jover R, Nakamura T, Castell JV. Human hepatocyte growth factor downregulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J Pharmacol Exp Ther. 1998;284:760-767.
31. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49:162-175.